Blood Samples to Identify Biomarkers in Haploidentical Graft Recipients

N/ACompletedNCT01141959

Fred Hutchinson Cancer Center11 enrolled

Overview

The investigators are interested in identifying patient-specific factors related to donor chimerism in patients who receive nonmyeloablative hematopoietic stem cell transplants from haploidentical donors. We will look how patients' bodies break down and immediately respond to cyclophosphamide, fludarabine and mycophenolate mofetil.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Leukemia Hodgkin Disease Non-Hodgkin Lymphoma Myelodysplastic Syndrome Multiple Myeloma

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Scheduled to receive nonmyeloablative conditioning which includes fludarabine * Scheduled to receive a haploidentical graft * Scheduled to receive postgrafting immunosuppression which includes oral mycophenolate mofetil (MMF) or enteric-coated mycophenolic acid * Age \>18 years at the time of enrollment Exclusion Criteria: * Diagnosed with an immunodeficiency disorder, including HIV

Locations (1)

Fred Hutchinson Cancer Research Center

Seattle, Washington, United States

Outcomes

Primary Outcomes

Donor T-cell chimerism

Time frame: Day 28 post-transplant

Secondary Outcomes

Exposure to cyclophosphamide, fludarabine, and mycophenolate mofetil and their breakdown products

Time frame: 1 week before through 3 weeks after transplant

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.